# A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis

> **NCT02970331** · PHASE2 · WITHDRAWN · sponsor: **Maruho Co., Ltd.**

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** pefcalcitol ointment, 0.005%

## Key facts

- **NCT ID:** NCT02970331
- **Lead sponsor:** Maruho Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** FDA requested us to stop the study
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02970331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02970331, "A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02970331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*